Korro Bio, Inc. Common Stock
KRROKorro Bio, Inc. (KRRO) is a biotechnology company focused on developing targeted gene editing and gene regulation therapies. The company specializes in leveraging innovative nucleic acid-based approaches to treat rare and serious diseases by directly modifying or regulating affected genes.
Company News
Korro Bio announced that CEO Ram Aiyar will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026. The biopharmaceutical company is focused on developing RNA editing genetic medicines for rare and prevalent diseases. A live webcast will be available on their investor relations website.
Korro Bio, a clinical-stage biopharmaceutical company, announced that the FDA has granted orphan drug designation to its investigational medicine KRRO-110 for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). KRRO-110 is currently being evaluated in a Phase 1/2a clinical study, and the company expects to report interim data in the second ha...
The article discusses four biotech companies leveraging AI and machine learning technology to improve drug discovery and development processes. These companies are Absci, Firefly Neuroscience, Korro Bio, and NeuroSense Therapeutics.
Novo Nordisk and Korro Bio announced a $530 million drug development collaboration, but this is not seen as a threat to Moderna as the companies are working on different approaches to mRNA technology.
CAMBRIDGE, Mass., May 20, 2024 (GLOBE NEWSWIRE) -- Â Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly prevalent diseases, is presenting new preclinical data demonstrating the specificity and the completion of a genetic mouse study and sustained ed...
